Detalhe da pesquisa
1.
Determining the lower limit of detection required for HCV viral load assay for test of cure following direct-acting antiviral-based treatment regimens: Evidence from a global data set.
J Viral Hepat
; 29(6): 474-486, 2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35278339
2.
The NAFLD-MAFLD debate: Eminence vs evidence.
Liver Int
; 41(2): 255-260, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33220154
3.
Efï¬cacy and safety of sofosbuvir-based therapy in hepatitis C virus recurrence post living donor liver transplant: A real life egyptian experience.
J Med Virol
; 91(4): 668-676, 2019 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-30549048
4.
Effect of treatment with direct acting antivirals on body mass index and hepatic steatosis in chronic hepatitis C.
J Med Virol
; 90(6): 1099-1105, 2018 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-29469217
5.
Novel scores combining AFP with non-invasive markers for prediction of liver fibrosis in chronic hepatitis C patients.
J Med Virol
; 90(6): 1080-1086, 2018 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-29315641
6.
Longitudinal assessment of hepatic fibrosis in responders to direct-acting antivirals for recurrent hepatitis C after liver transplantation using noninvasive methods.
Clin Transplant
; 32(8): e13334, 2018 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-29935046
7.
Efficacy and safety of ombitasvir/paritaprevir/ritonavir-based therapy in HCV patients with chronic kidney disease.
Arab J Gastroenterol
; 24(1): 29-33, 2023 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-36813580
8.
Identifying Different Mutation Sites Leading to Resistance to the Direct-Acting Antiviral (DAA) Sofosbuvir in Hepatitis C Virus Patients from Egypt.
Microorganisms
; 10(4)2022 Mar 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-35456731
9.
The egyptian clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease.
Saudi J Gastroenterol
; 28(1): 3-20, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35083973
10.
Assessment of facility performance during mass treatment of chronic hepatitis C in Egypt: Enablers and obstacles.
J Infect Public Health
; 13(9): 1322-1329, 2020 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-32473817
11.
High SVR rate following retreatment of non-sustained virological responders to sofosbuvir based anti-HCV therapies regardless of RAS testing: A real-life multicenter study.
Expert Rev Gastroenterol Hepatol
; 13(9): 907-914, 2019 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-31173527
12.
Hepatitis C virus treatment by direct-acting antivirals in successfully treated hepatocellular carcinoma and possible mutual impact.
Eur J Gastroenterol Hepatol
; 30(8): 876-881, 2018 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-29727383
13.
Establishing ultrasound based transient elastography cutoffs for different stages of hepatic fibrosis and cirrhosis in Egyptian chronic hepatitis C patients.
Arab J Gastroenterol
; 18(4): 210-215, 2017 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-29187317
14.
Hemochromatosis Gene Polymorphism as a Predictor of Sustained Virological Response to Antiviral Treatment in Egyptian Chronic Hepatitis C Patients.
Euroasian J Hepatogastroenterol
; 7(2): 154-157, 2017.
Artigo
em Inglês
| MEDLINE | ID: mdl-29201799
15.
Serious Adverse Events with Sofosbuvir Combined with Interferon and Ribavirin: Real-Life Egyptian Experience.
J Interferon Cytokine Res
; 37(8): 348-353, 2017 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-28777714